PTH and chronic kidney disease: In particular, De Jong and colleagues ascertained a significant increase in serum phosphate (9%), FGF-23 (19%), and parathormone PTH (16%) in a cohort of 31 patients with T2D with CKD stages 2 to 4 and albuminuria who were treated with dapagliflozin for six weeks.